IU/JAX/Pitt MODEL-AD: Murinizing Aducanumab
IU/JAX/Pitt MODEL-AD:Murinizing Aducanumab
基本信息
- 批准号:10094809
- 负责人:
- 金额:$ 39.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-30 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAducanumabAlzheimer disease preventionAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer’s disease biomarkerAnimal Disease ModelsAnimal ModelAreaAwardBiologicalCause of DeathCessation of lifeClinicalClinical TrialsCommunitiesDataData SetDementiaDevelopmentDiseaseDisease modelDrug IndustryEarly DiagnosisEffectivenessElderlyEtiologyFundingGenesGenetic ModelsGoalsGrowthHumanIndianaInfrastructureInstitutionInternationalInterventionLaboratoriesMammalian GeneticsMedicalModelingNerve DegenerationParentsPreclinical TestingPrevalenceProcessResearchTestingTherapeuticUnited StatesUnited States National Institutes of HealthUniversitiesVariantdata resourcedisabilitydrug testinggenetic technologyhuman diseaseinnovationinsightmouse modelmultidisciplinaryneuroimagingnext generationnovelnovel therapeuticspre-clinicalpreclinical studypreventsymposium
项目摘要
PROJECT SUMMARY FOR FUNDED PARENT AWARD (OVERALL)
Alzheimer's disease (AD) is a major cause of dementia, disability and death in the elderly. Despite recent
advances in our understanding of basic biological mechanisms underlying AD, we do not yet know how to prevent
AD or have an approved disease modifying intervention. Both are essential to slow or stop the growth in dementia
prevalence. The National Alzheimer's Project Act (NAPA) seeks to prevent and effectively treat AD by 2025
through innovative research on etiology, early detection, and therapeutics. In support of NAPA's goals, one of
the targeted areas of research identified at the NIA sponsored 2015 Alzheimer's Disease Research Summit was
the development of the next generation of animal models of AD that will prove more predictive in preclinical
studies and thus accelerate the drug testing pipeline. While our current animal models of AD have provided
multiple novel insights into AD disease mechanisms, thus far they have not been successfully utilized to predict
the effectiveness of therapies that have moved into AD clinical trials. The Indiana University (IU)/Jackson
Laboratory (JAX) Alzheimer's Disease Precision Models Center (IU/JAX ADPMC) will leverage IU's
strengths in neurodegenerative research including 25 years as an NIA-supported Alzheimer's Disease
Center (ADC) and considerable expertise in preclinical drug testing with JAX's eight decades of expertise
in mammalian genetics and disease modeling to develop, validate and disseminate new, precise animal
models of Alzheimer's disease (AD). In addition, the IU/JAX ADMPC contains Sage Bionetworks to provide
expertise in data organization and dissemination. The IU/JAX ADPMC brings together an international,
multi-disciplinary team—including geneticists and genetics technology experts, quantitative and
computational biologists, clinical experts in AD and neuroimaging, pharmacologists and world leaders in
the development of precision animal models of disease—that possesses the collective ability to foresee
disease modeling needs as they emerge on the international stage. This will allow the IU/JAX ADPMC to
serve the AD scientific community effectively and efficiently. The IU/JAX ADPMC will generate new AD
modeling processes and pipelines, data resources, research results and models that will be swiftly shared
through JAX's and Sage's proven dissemination pipelines and through the NIA-supported AD Centers,
academic medical centers, research institutions and the pharmaceutical industry worldwide. Ultimately, this
will accelerate the application of advances in animal models for the greatest possible medical benefit. The
Specific Aims of the IU/JAX ADPMC are:
1. Maximize Human Datasets to Identify Putative Variants, Genes and Biomarkers for AD.
2. Generate and Characterize the Next Generation of Mouse Models of AD.
3. Validate the Next Generation of Mouse Models of AD and Develop a Preclinical Testing Pipeline.
资助奖学金项目摘要(总体)
阿尔茨海默病(AD)是老年人痴呆、残疾和死亡的主要原因。尽管最近
虽然我们对AD的基本生物学机制的理解有所进步,但我们还不知道如何预防
AD或有批准的疾病修饰干预。两者都是减缓或阻止痴呆症增长的关键
普遍性。国家阿尔茨海默病项目法案(NAPA)旨在到2025年预防和有效治疗AD
通过对病因学、早期发现和治疗方法的创新研究。为支持国家适应行动方案的目标,
在NIA赞助的2015年阿尔茨海默病研究峰会上确定的目标研究领域是
下一代AD动物模型的开发,将证明在临床前研究中更具预测性。
研究,从而加快药物测试管道。虽然我们目前的AD动物模型提供了
对AD疾病机制的多种新见解,迄今为止尚未成功地用于预测
已经进入AD临床试验的治疗方法的有效性。印第安纳州大学/杰克逊
实验室(JAX)阿尔茨海默病精密模型中心(IU/JAX ADPMC)将利用IU的
在神经退行性疾病研究方面的优势,包括25年的NIA支持的阿尔茨海默病
中心(ADC)和相当的专业知识,在临床前药物测试与JAX的八十年的专业知识
在哺乳动物遗传学和疾病建模,开发,验证和传播新的,精确的动物
阿尔茨海默病(AD)的模型。此外,IU/JAX ADMPC包含Sage Bionetworks,
数据组织和传播方面的专门知识。IU/JAX ADPMC汇集了一个国际,
多学科团队-包括遗传学家和遗传技术专家,定量和
计算生物学家、AD和神经影像学临床专家、药理学家和
发展精确的疾病动物模型,
疾病建模需求,因为它们出现在国际舞台上。这将允许IU/JAX ADPMC
有效和高效地为AD科学界服务。IU/JAX ADPMC将生成新的AD
建模流程和管道、数据资源、研究成果和模型将迅速共享
通过JAX和Sage经过验证的传播渠道,以及通过NIA支持的广告中心,
学术医疗中心,研究机构和全球制药行业。最终这
将加速动物模型的应用,以获得最大的医疗效益。的
IU/JAX ADPMC的具体目标是:
1.最大化人类数据集,以确定AD的假定变体,基因和生物标志物。
2.生成和表征下一代AD小鼠模型。
3.开发下一代AD小鼠模型并开发临床前测试管道。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory W Carter其他文献
Genetic interactions improve models of quantitative traits
遗传相互作用改进数量性状模型
- DOI:
10.1038/ng.3829 - 发表时间:
2017-03-30 - 期刊:
- 影响因子:29.000
- 作者:
Anna L Tyler;Gregory W Carter - 通讯作者:
Gregory W Carter
Gregory W Carter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory W Carter', 18)}}的其他基金
An Explainable Unified AI Strategy for Efficient and Robust Integrative Analysis of Multi-omics Data from Highly Heterogeneous Multiple Studies
一种可解释的统一人工智能策略,用于对来自高度异质性多项研究的多组学数据进行高效、稳健的综合分析
- 批准号:
10729965 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease
阿尔茨海默病狨猴模型的生成、表征和验证
- 批准号:
10494769 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Project 2: Identify and enhance LOAD-related signatures in outbred and genetically-engineered marmosets
项目 2:识别并增强近交系和基因工程狨猴中与 LOAD 相关的特征
- 批准号:
10494776 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Modeling the Genetic Interaction Between Klotho and APOE Alleles in Alzheimer's Disease
模拟阿尔茨海默病中 Klotho 和 APOE 等位基因之间的遗传相互作用
- 批准号:
10524407 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease
阿尔茨海默病狨猴模型的生成、表征和验证
- 批准号:
10819807 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Open Drug Discovery Center for Alzheimer's Disease
阿尔茨海默病开放药物发现中心
- 批准号:
10250427 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
Open Drug Discovery Center for Alzheimer's Disease
阿尔茨海默病开放药物发现中心
- 批准号:
10017132 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
IU/JAX/Pitt MODEL-AD: Deep Phenotyping Proteomics Year 1
IU/JAX/Pitt MODEL-AD:深度表型蛋白质组学第 1 年
- 批准号:
10092243 - 财政年份:2016
- 资助金额:
$ 39.63万 - 项目类别:
The IU/JAX Alzheimer's Disease Precision Models Center: Metabolomics
IU/JAX 阿尔茨海默病精密模型中心:代谢组学
- 批准号:
9537115 - 财政年份:2016
- 资助金额:
$ 39.63万 - 项目类别: